FIELD: medicine; cardiology.
SUBSTANCE: offered is application of Valsartan or its pharmaceutically acceptable salt combined other admissible reactants chosen from group, including Alacepril, Benasepril, Benaseprilat, Captopril, Ceronapril, Silazapril, Delapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moveltopril, Perindopril, Chinapril, Ramipril, Spirapril, Temocapril and Trandolapril for preparation of medical product for treatment of acute myocardial infarction.
EFFECT: lower death rate of patients resulted from combinative application of Valsartan and Captopril in comparison with independent introduction thereof.
3 cl, 6 tbl
Authors
Dates
2009-02-10—Published
2006-10-05—Filed